WO2025036476 - ANTI-B7-H3 ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2025/036476
Publication Date
20.02.2025
International Application No.
PCT/CN2024/112650
International Filing Date
16.08.2024
Title **
[English]
ANTI-B7-H3 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-B7-H3 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
LI, Peiran
GUO, Yanan
Priority Data
PCT/CN2023/113363
16.08.2023
CN
PCT/CN2023/113350
16.08.2023
CN
PCT/CN2023/113348
16.08.2023
CN
PCT/CN2024/105244
12.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3408 | |
| EPO | Filing, Examination, Granting | 36065 | |
| Japan | Filing, Examination, Granting | 3355 | |
| South Korea | Filing, Examination, Granting | 4826 | |
| USA | Filing, Examination, Granting | 18740 |
Total:
66,394
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are anti-B7-H3 (B7 Homolog 3) antibodies, antigen-binding fragments thereof, ADCs, and the uses thereof.[French]
L'invention concerne des anticorps anti-B7-H3 (homologue 3 de B7), des fragments de liaison à l'antigène de ceux-ci, des conjugués anticorps-médicament (ADC) et leurs utilisations.